UNSPSC 51292500: Antidepressant benzimidazoles

Antidepressant drugs made from compounds with a benzene fused to imidazoles.

UNSPSC 51292500 Antidepressant benzimidazoles is a Class code that does not align with the state and local procurement activity currently tagged under it. The recent opportunities in this code track show no solicitations for antidepressant medications; instead, they reflect purchases of naloxone (an opioid antagonist used in overdose response), generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploratory vendor inquiry into direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope and the actual work being solicited signals that this code sees little relevant recent activity in state and local procurement for the class of medications it nominally describes.

The issuing bodies posting under this code represent a mix of county health departments, state health and human services agencies, and cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023 as stated in the source, though this date appears inconsistent with the posting date) to procure naloxone and safe drug deactivation systems—1,900 units and 800 systems annually with quarterly deliveries to the county's Community Health Building. The Texas Health and Human Services Commission issued a Request for Information in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, a preliminary market-intelligence phase before formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness set for July 1, 2026. Activity appears concentrated in the South and Upper Midwest, with no recent opportunities in other regions represented in the source.